Anaplastic thyroid cancer: Unveiling advances in diagnosis and management DOI
Treshita Dey, Budhi Singh Yadav

World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(7), P. 786 - 789

Published: July 16, 2024

The review article by Pavlidis

Language: Английский

Interaction between tumor stage and age on survival outcomes of patients with anaplastic thyroid cancer DOI
Ayrton Bangolo, Auda Auda, John Bukasa-Kakamba

et al.

World Journal of Experimental Medicine, Journal Year: 2024, Volume and Issue: 14(3)

Published: Aug. 28, 2024

Anaplastic thyroid cancer (ATC) is an aggressive, rare malignancy associated with rapid growth and metastasis, a very poor prognosis. We investigated the clinical characteristics, survival outcomes independent prognostic factors anaplastic cancer.

Language: Английский

Citations

0

Efficacy and Safety of Pazopanib in the Treatment of Thyroid Cancer: A Systematic Review DOI Creative Commons

Alexandra Laura Mederle,

Loredana Gabriela Stana,

Adrian Cosmin Ilie

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2820 - 2820

Published: Dec. 12, 2024

Pazopanib, a multi-targeted tyrosine kinase inhibitor, has been explored for its efficacy in treating various subtypes of thyroid cancer, including differentiated carcinoma (DTC), medullary (MTC), and anaplastic (ATC). This systematic review assesses the safety pazopanib, focusing on progression-free survival (PFS), overall (OS), response rates adverse events. A comprehensive search was conducted databases PubMed, Scopus, Web Science up to October 2024 identify randomized controlled trials phase II clinical that investigated use pazopanib cancer. The PRISMA guidelines were followed data extraction quality assessment. included six studies encompassing 289 patients, presenting overview pazopanib’s application across different cancer subtypes. reported median PFS ranging from 2.1 11.7 months OS 5.7 not reached. partial varied 5% 49%. Adverse events common, with hypertension occurring 71.7% fatigue diarrhea also frequently reported. Grade 3–5 led treatment discontinuations 14% patients. Pazopanib shows variable types, offering significant benefits MTC refractory DTC terms but limited impact ATC. event profile necessitates careful management, particularly regarding other treatment-related toxicities. Further are required refine therapeutic protocols exploring combination therapies may enhance reduce outcomes.

Language: Английский

Citations

0

Anaplastic thyroid cancer: Unveiling advances in diagnosis and management DOI
Treshita Dey, Budhi Singh Yadav

World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(7), P. 786 - 789

Published: July 16, 2024

The review article by Pavlidis

Language: Английский

Citations

0